ArticleQuantitative imaging in medicine and surgery2023
Article in Quantitative imaging in medicine and surgery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methods: A total of 62 patients with DM who underwent Results: The median duration of follow-up was 36 [interquartile range (IQR), 14-53] months. The survival rates were 85.2% and 73.4% for 1 and 5 years, respectively. A total of 13 (21.0%) patients died during a median follow-up of 7 (IQR, 4-15.5) months. Compared with the survival group, the death group had significantly higher levels of C-reactive protein [CRP; median (IQR), 4.2 (3.0, 6.0) Conclusions: Pulmonary FDG uptake and EFV detected with PET-CT were independent risk factors for death in patients with DM and without malignant tumors. Patients with the concurrent presence of high pulmonary FDG uptake and high EFV had a worse prognosis compared with patients with 1 or neither of these two risk factors. Early treatment should be applied in patients with concurrent presence of high pulmonary FDG uptake and high EFV to improve the survival rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.